Overcoming Immune Evasion in T Cell Therapy of Cancer: Lessons from Animal Models

Title: Overcoming Immune Evasion in T Cell Therapy of Cancer: Lessons from Animal Models

Volume: 8 Issue: 1

Author(s): Xue-Feng Bai and Jin-Qing Liu

Affiliation:

Keywords: Cytotoxic T lymphocytes, adoptive T cell therapy, cancer immune evasion

Abstract: Cancer antigen-specific cytotoxic T lymphocytes (CTL) are the major effectors against cancer cells. However, large established tumors are usually not fully controlled by CTL for at least two reasons. First, large established tumors have immune suppressive networks that not only suppress CTL effector function but also permit tumor progression. Second, the genetic instability of cancer cells often results in the selection of antigenic variants by CTL, which allow cancer cells to escape destruction. Simply enhancing T cell capacity may not fully control large established tumors. Other measures, such as enhancing local costimulation, inhibiting angiogenesis and down-regulating functions of tumor associated myeloid cells should also be considered. In this paper we will review some of the progress from animal studies.

Cite this article as:

Bai Xue-Feng and Liu Jin-Qing, Overcoming Immune Evasion in T Cell Therapy of Cancer: Lessons from Animal Models, Current Molecular Medicine 2008; 8 (1) . https://dx.doi.org/10.2174/156652408783565531